[go: up one dir, main page]

CN1293038C - Prepn process of (1R, 2S)-(-)-ephedrine or its hydrochloride - Google Patents

Prepn process of (1R, 2S)-(-)-ephedrine or its hydrochloride Download PDF

Info

Publication number
CN1293038C
CN1293038C CNB2004100249538A CN200410024953A CN1293038C CN 1293038 C CN1293038 C CN 1293038C CN B2004100249538 A CNB2004100249538 A CN B2004100249538A CN 200410024953 A CN200410024953 A CN 200410024953A CN 1293038 C CN1293038 C CN 1293038C
Authority
CN
China
Prior art keywords
methylaminopropiophenone
acid
ephedrine
metal borohydride
hydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB2004100249538A
Other languages
Chinese (zh)
Other versions
CN1706812A (en
Inventor
黄成军
周后元
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ZHEJIANG APELOA KANGYU PHARMACEUTICAL CO Ltd
Shanghai Institute of Pharmaceutical Industry
Apeloa Pharmaceutical Co Ltd
Original Assignee
Shanghai Institute of Pharmaceutical Industry
Zhejiang Kangyu Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Pharmaceutical Industry, Zhejiang Kangyu Pharmaceutical Co Ltd filed Critical Shanghai Institute of Pharmaceutical Industry
Priority to CNB2004100249538A priority Critical patent/CN1293038C/en
Priority to PCT/CN2005/000743 priority patent/WO2005121066A1/en
Publication of CN1706812A publication Critical patent/CN1706812A/en
Application granted granted Critical
Publication of CN1293038C publication Critical patent/CN1293038C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention relates to a method for preparing (1R, 2S)-(-)-ephedrine by using [(S)-(-)-alpha-methylamino propiophenone]2. (2R, 3R)-tartaric derivative or salt prepared from (S)-(-)-alpha-methylamino propiophenone and other kinds of organic acid as raw materials to react with a mixture composed of metal borohydride or metal borohydride and lewis acid. The reaction raw materials are not despun in the process of reduction, the ephedrine in reduction products has a very strong effect, and the utilization rate of metal borohydride is high.

Description

(1R,2S)-(-)-麻黄碱或其盐酸盐的制备方法(1R, 2S)-(-)-ephedrine or its hydrochloride preparation method

技术领域technical field

本发明涉及(1R,2S)-(-)-麻黄碱或其盐酸盐的制备方法。The invention relates to a preparation method of (1R, 2S)-(-)-ephedrine or its hydrochloride.

背景技术Background technique

(1R,2S)-(-)-麻黄碱是一种重要的医药产品,临床上主要用于防治某些低血压状态,特别是椎管麻醉或硬膜外麻醉时预防血压下降;治疗鼻粘膜充血肿胀引起的鼻塞;预防或缓解支气管哮喘发作;缓解荨麻疹和血管神经性水肿的皮肤粘膜症状。其化学结构式如下:(1R, 2S)-(-)-ephedrine is an important medicinal product, which is mainly used clinically to prevent and treat certain hypotensive states, especially to prevent blood pressure drop during spinal anesthesia or epidural anesthesia; to treat nasal mucosa Nasal congestion caused by congestion and swelling; prevention or relief of bronchial asthma attacks; relief of skin and mucous membrane symptoms of urticaria and angioedema. Its chemical structural formula is as follows:

传统的麻黄碱的生产方法是萃取法,即提取天然麻黄草中的麻黄碱,但麻黄草是固沙植物,长期的滥采滥挖导致产草面积和产草量下降,产地沙化日益严重。The traditional production method of ephedrine is the extraction method, that is, the ephedrine in the natural ephedra is extracted, but ephedra is a sand-fixing plant, and long-term indiscriminate mining and digging lead to a decrease in the grass-producing area and yield, and the desertification of the production area is becoming more and more serious.

另一种生产麻黄碱的方法是生物半合成法。以苯甲醛为起始原料,通过酵母或酵母固定化细胞来合成(R)-苯基乙酰基甲醇,再经化学转化制备(1R,2S)-(-)-麻黄碱。德国和捷克采用该方法生产,工艺较复杂。Another method of producing ephedrine is biosynthesis. Using benzaldehyde as a starting material, yeast or yeast immobilized cells are used to synthesize (R)-phenylacetylcarbinol, and then chemically transform to prepare (1R, 2S)-(-)-ephedrine. Germany and the Czech Republic adopt this method to produce, and the process is more complicated.

由于化学合成法不受自然资源的限制,且可据市场需求变化调整产量,方法也不太复杂。为此,化学合成麻黄成为人们是否关注的课题。Because the chemical synthesis method is not limited by natural resources, and the output can be adjusted according to changes in market demand, the method is not too complicated. For this reason, whether chemically synthesized ephedra becomes the subject that people pay close attention to.

通常以催化氢化或金属硼氢化物还原α-甲胺基苯丙酮或其盐酸盐制备麻黄碱。Ephedrine is usually prepared by catalytic hydrogenation or metal borohydride reduction of α-methylaminopropiophenone or its hydrochloride.

J.F.Hyde等以PtO2催化还原α-甲胺基苯丙酮(J.F.Hyde,E.Browning,J.Chem.Soc.,2287(1928));JF Hyde et al. Catalyzed the reduction of α-methylaminopropiophenone with PtO2 (JF Hyde, E. Browning, J. Chem. Soc., 2287 (1928));

I.K.Fel’dman等以Raney Ni催化还原α-甲胺基苯丙酮(I.K.Fel’dman,N.N.Bel’stova,Zh.Priklad.khim.,35(6),1364(1962);CA 57:11064);I.K.Fel'dman etc. use Raney Ni to catalyze the reduction of α-methylaminopropiophenone (I.K.Fel'dman, N.N.Bel'stova, Zh.Priklad.khim., 35(6), 1364(1962); CA 57:11064) ;

Ger(East)11332以Raney Ni催化还原α-甲胺基苯丙酮盐酸盐;Ger(East)11332 catalyzed the reduction of α-methylaminopropiophenone hydrochloride with Raney Ni;

H.Takamatsu以金属铂催化还原手性α-甲胺基苯丙酮盐酸盐,或以LiAlH4、NaBH4还原手性α-甲胺基苯丙酮(H.Takamatsu,J.Pharm.Soc,Japan,76,1219(1956))。H.Takamatsu catalyzed the reduction of chiral α-methylaminopropiophenone hydrochloride with metal platinum, or reduced chiral α-methylaminopropiophenone with LiAlH 4 , NaBH 4 (H.Takamatsu, J.Pharm.Soc, Japan , 76, 1219 (1956)).

上述文献以催化氢化法或金属硼氢化物还原α-甲胺基苯丙酮或手性α-甲胺基苯丙酮,其产物中含有较多的伪麻黄碱,可达25.9%,需加以分离;而且由于α-甲胺基苯丙酮较易烯醇化,特别在碱性条件下,导致手性α-甲胺基苯丙酮在还原的过程中消旋。如以Raney Ni催化还原手性α-甲胺基苯丙酮盐酸盐,Raney Ni易失活,而Pd/C催化还原手性α-甲胺基苯丙酮盐酸盐,则成本太高;金属硼氢化物还原手性α-甲胺基苯丙酮盐酸盐,则在还原羰基的同时,金属硼氢化物也会与盐酸盐中的氯化氢反应,增加了金属硼氢化物的消耗。The above-mentioned documents reduce α-methylaminopropiophenone or chiral α-methylaminopropiophenone with catalytic hydrogenation method or metal borohydride, and contain more pseudoephedrine in its product, can reach 25.9%, need to be separated; And because α-methylaminopropiophenone is easier to enolize, especially under alkaline conditions, resulting in the racemization of chiral α-methylaminopropiophenone during the reduction process. If Raney Ni is used to catalyze the reduction of chiral α-methylaminopropiophenone hydrochloride, Raney Ni is easy to deactivate, while Pd/C catalyzes the reduction of chiral α-methylaminopropiophenone hydrochloride, the cost is too high; metal Borohydride reduction of chiral α-methylaminopropiophenone hydrochloride, while reducing carbonyl, metal borohydride will also react with hydrogen chloride in hydrochloride, increasing the consumption of metal borohydride.

发明内容Contents of the invention

本发明需要解决的技术问题是公开一种(1R,2S)-(-)-麻黄碱或其盐酸盐的制备方法,以克服现有技术存在的上述缺陷,满足医药领域发展的需要。The technical problem to be solved in the present invention is to disclose a preparation method of (1R, 2S)-(-)-ephedrine or its hydrochloride, so as to overcome the above-mentioned defects in the prior art and meet the needs of the development of the medical field.

本发明的步骤如下:The steps of the present invention are as follows:

将还原剂加入含有反应原料的溶剂中,在-20~35℃下进行还原反应。反应结束后,可采用常规的方法从反应产物中收集(1R,2S)-(-)-麻黄碱,如可先回收反应溶剂,然后加酸分解未反应的金属硼氢化物,并回收有机酸,然后向酸水层加碱以游离还原产物;或在回收溶剂后先加碱调体系的pH值至强碱性,此时有机酸与碱成盐,溶于水中,还原产物则游离出。然后以有机溶剂萃取还原产物,与盐酸成盐,浓缩,重结晶后可得高纯度的(1R,2S)-(-)-麻黄碱盐酸盐。The reducing agent is added into the solvent containing the reaction raw materials, and the reduction reaction is carried out at -20-35°C. After the reaction finishes, conventional methods can be adopted to collect (1R, 2S)-(-)-ephedrine from the reaction product, as the reaction solvent can be reclaimed first, then the unreacted metal borohydride is decomposed with acid, and the organic acid is reclaimed , and then add alkali to the acidic water layer to free the reduction product; or add alkali to adjust the pH value of the system to strong alkalinity after recovering the solvent. At this time, the organic acid and alkali form a salt, dissolve in water, and the reduced product is released. Then extract the reduced product with an organic solvent, form a salt with hydrochloric acid, concentrate, and recrystallize to obtain high-purity (1R, 2S)-(-)-ephedrine hydrochloride.

所说的还原剂为金属硼氢化物或金属硼氢化物与路易斯酸组成的混合物;The reducing agent is metal borohydride or a mixture of metal borohydride and Lewis acid;

所说的反应原料包括[(S)-(-)-α-甲胺基苯丙酮]2·(2R,3R)-(-)-二苯甲酰基酒石酸、[(S)-(-)-α-甲胺基苯丙酮]2·(2R,3R)-(-)-二对甲基苯甲酰基酒石酸、[(S)-(-)-α-甲胺基苯丙酮]2·(2R,3R)-(-)-二间甲基苯甲酰基酒石酸、[(S)-(-)-α-甲胺基苯丙酮]2·(2R,3R)-(-)-二邻甲基苯甲酰基酒石酸、[(S)-(-)-α-甲胺基苯丙酮]2·(2R,3R)-(-)-二乙酰基酒石酸、[(S)-(-)-α-甲胺基苯丙酮]2·邻苯二甲酸、[(S)-(-)-α-甲胺基苯丙酮]2·d-酒石酸、、(S)-(-)-α-甲胺基苯丙酮·苯甲酸、(S)-(-)-α-甲胺基苯丙酮·苹果酸及(S)-(-)-α-甲胺基苯丙酮·乳酸中的一种;Said reaction materials include [(S)-(-)-α-methylaminopropiophenone] 2 ·(2R,3R)-(-)-dibenzoyl tartaric acid, [(S)-(-)- α-methylaminopropiophenone] 2 ·(2R, 3R)-(-)-di-p-toluoyl tartaric acid, [(S)-(-)-α-methylaminopropiophenone] 2 ·(2R ,3R)-(-)-Di-m-methylbenzoyl tartaric acid, [(S)-(-)-α-methylaminopropiophenone] 2 ·(2R,3R)-(-)-Di-o-methyl Benzoyl tartaric acid, [(S)-(-)-α-methylaminopropiophenone] 2 · (2R,3R)-(-)-diacetyl tartaric acid, [(S)-(-)-α- Methylaminopropiophenone] 2 phthalic acid, [(S)-(-)-α-methylaminopropiophenone] 2 d-tartaric acid, (S)-(-)-α-methylamino One of propiophenone·benzoic acid, (S)-(-)-α-methylaminopropiophenone·malic acid and (S)-(-)-α-methylaminopropiophenone·lactic acid;

所述及的反应原料可采用文献(H.Takamatsu,J.Pharm.Soc.Japan,76,1219(1956))公开的方法进行制备或采用市售产品;The mentioned reaction raw materials can be prepared by the methods disclosed in the literature (H.Takamatsu, J.Pharm.Soc.Japan, 76, 1219 (1956)) or commercially available products;

所说的溶剂选自水、C1~C5的醇或水与C1~C5的醇组成的混合物;The solvent is selected from water, C1-C5 alcohol or a mixture of water and C1-C5 alcohol;

所说的金属硼氢化物选自KBH4、NaBH4、Zn(BH4)2、LiBH4或Ca(BH4)2中的一种,所说的路易斯酸选自AlCl3、CaCl2或ZnCl2The metal borohydride is selected from one of KBH 4 , NaBH 4 , Zn(BH 4 ) 2 , LiBH 4 or Ca(BH 4 ) 2 , and the Lewis acid is selected from AlCl 3 , CaCl 2 or ZnCl 2 .

反应原料与还原剂的摩尔比为:反应原料∶还原剂=1∶0.5~3。The molar ratio of the reaction raw material to the reducing agent is: reaction raw material: reducing agent=1:0.5-3.

本发明的方法有如下特点:Method of the present invention has following characteristics:

1.(S)-(-)-α-甲胺基苯丙酮的有机酸盐中的(S)-(-)-α-甲胺基苯丙酮在还原的过程中不消旋。研究表明:(S)-(-)-α-甲胺基苯丙酮有机酸盐的消旋速度比其游离碱要慢得多。反应结束后,以毛细管电泳法对还原粗产物的光学纯度进行了分析测定,麻黄碱的对映体过量达97.2%,表明(S)-(-)-α-甲胺基苯丙酮有机酸盐中的(S)-(-)-α-甲胺基苯丙酮在还原的过程中基本没有消旋。1. The (S)-(-)-α-methylaminopropiophenone in the organic acid salt of (S)-(-)-α-methylaminopropiophenone does not racemize during the reduction process. Studies have shown that the racemization rate of (S)-(-)-α-methylaminopropiophenone organic acid salt is much slower than that of its free base. After the reaction, the optical purity of the reduced crude product was analyzed and determined by capillary electrophoresis, and the enantiomeric excess of ephedrine reached 97.2%, showing that (S)-(-)-α-methylaminopropiophenone organic acid salt The (S)-(-)-α-methylaminopropiophenone in the reduction process basically has no racemization.

2.实验结果表明,本法获得麻黄碱的选择性增加,产物中麻黄碱占绝对优势,其重量含量在92-98%,见表1。如此,在还原结束后,只需对还原粗产物的盐酸盐重结晶,便可得到高纯度的(1R,2S)-(-)-麻黄碱盐酸盐。2. experimental result shows, this method obtains the selectivity increase of ephedrine, and ephedrine occupies an absolute advantage in the product, and its weight content is at 92-98%, see Table 1. In this way, after the reduction, only the hydrochloride of the reduced crude product needs to be recrystallized to obtain high-purity (1R, 2S)-(-)-ephedrine hydrochloride.

3.金属硼氢化物的利用率相当高。由于(S)-(-)-α-甲胺基苯丙酮与有机酸所成的盐呈中性,所以除羰基被还原外,不另外增加金属硼氢化物的消耗,基本上达到硼氢化物的理论利用率;3. The utilization rate of metal borohydride is quite high. Since the salt of (S)-(-)-α-methylaminopropiophenone and organic acid is neutral, except for the reduction of the carbonyl group, it does not increase the consumption of metal borohydride, basically reaching the borohydride theoretical utilization;

4.游离的α-甲胺基苯丙酮与金属硼氢化物或金属硼氢化物与路易斯酸组成的混合物于室温下不反应,需加热至50℃,但在此温度下,α-甲胺基苯丙酮不稳定,收率降低。而(S)-(-)-α-甲胺基苯丙酮有机酸与金属硼氢化物或金属硼氢化物与路易斯酸组成的混合物在室温附近就可发生反应,减少了副反应,提高了还原收率。4. The mixture of free α-methylaminopropiophenone and metal borohydride or metal borohydride and Lewis acid does not react at room temperature and needs to be heated to 50°C, but at this temperature, α-methylamino Propiophenone is unstable and the yield decreases. The mixture of (S)-(-)-α-methylaminopropiophenone organic acid and metal borohydride or metal borohydride and Lewis acid can react at room temperature, reducing side reactions and improving reduction yield.

表1:还原产物中,麻黄碱与伪麻黄碱的比例   原料   麻黄碱∶伪麻黄碱   [(S)-(-)-α-甲胺基苯丙酮]2·(2R,3R)-(-)-二苯甲酰基酒石酸   95.3∶4.7   [(S)-(-)-α-甲胺基苯丙酮]2·(2R,3R)-(-)-二对甲基苯甲酰基酒石酸   98.0∶2.0   [(S)-(-)-α-甲胺基苯丙酮]2·邻苯二甲酸   98.6∶1.4   [(S)-(-)-α-甲胺基苯丙酮]2·d-酒石酸   99.0∶1.0   (S)-(-)-α-甲胺基苯丙酮   74.1∶25.9 Table 1: The ratio of ephedrine and pseudoephedrine in the reduction product raw material Ephedrine: Pseudoephedrine [(S)-(-)-α-Methylaminopropiophenone] 2 ·(2R,3R)-(-)-Dibenzoyltartaric acid 95.3:4.7 [(S)-(-)-α-Methylaminopropiophenone] 2 ·(2R,3R)-(-)-Di-p-methylbenzoyl tartaric acid 98.0:2.0 [(S)-(-)-α-Methylaminopropiophenone] 2 Phthalic acid 98.6:1.4 [(S)-(-)-α-Methylaminopropiophenone] 2 d-Tartrate 99.0:1.0 (S)-(-)-α-Methylaminopropiophenone 74.1:25.9

具体实施方式Detailed ways

                            实施例1Example 1

将20.0g[(S)-(-)-α-甲胺基苯丙酮]2·(2R,3R)-(-)-二苯甲酰基酒石酸置于80ml水中,搅拌下缓慢加入0.8gKBH4,反应15min。加入浓盐酸至pH值为2左右,以20ml×3乙酸乙酯萃取水层,浓缩,得(2R,3R)-(-)-二苯甲酰基酒石酸。以30%氢氧化钠水溶液调节酸水层的pH值至14,有油状物析出,以甲苯20ml×3萃取,浓缩甲苯层,得(1R,2S)-(-)-麻黄碱和少许(+)-伪麻黄碱。Put 20.0g of [(S)-(-)-α-methylaminopropiophenone] 2 ·(2R,3R)-(-)-dibenzoyltartaric acid in 80ml of water, slowly add 0.8gKBH 4 under stirring, React for 15 minutes. Add concentrated hydrochloric acid until the pH value is about 2, extract the aqueous layer with 20ml×3 ethyl acetate, and concentrate to obtain (2R,3R)-(-)-dibenzoyltartaric acid. Adjust the pH value of the acidic water layer to 14 with 30% sodium hydroxide aqueous solution, and an oily substance precipitates out, extracts with toluene 20ml×3, and concentrates the toluene layer to obtain (1R, 2S)-(-)-ephedrine and a little (+ )-pseudoephedrine.

其盐酸盐制备如下:Its hydrochloride was prepared as follows:

以4N盐酸中和甲苯层至pH值6,分去甲苯,水层浓缩,得白色固体,以水重结晶,得8.2g(1R,2S)-(-)-麻黄碱盐酸盐,mp217.5-218.5℃,[α]D-34.2°(c=5.0,H2O),收率:69.5%。Neutralize the toluene layer with 4N hydrochloric acid to a pH value of 6, remove the toluene, and concentrate the water layer to obtain a white solid, which is recrystallized with water to obtain 8.2 g of (1R, 2S)-(-)-ephedrine hydrochloride, mp217. 5-218.5°C, [α] D -34.2° (c=5.0, H 2 O), yield: 69.5%.

                         实施例2Example 2

将19.7g[(S)-(-)-α-甲胺基苯丙酮]2·邻苯二甲酸置于40ml水和40ml乙醇中,搅拌下缓慢加入0.7gKBH4,反应15min。浓缩以回收乙醇,然后加入30%氢氧化钠水溶液至pH至10,有油状物析出,以甲苯20ml×3萃取,浓缩,得(1R,2S)-(-)-麻黄碱和少许伪麻黄碱。Put 19.7g of [(S)-(-)-α-methylaminopropiophenone] 2 ·phthalic acid in 40ml of water and 40ml of ethanol, slowly add 0.7g of KBH 4 under stirring, and react for 15min. Concentrate to recover ethanol, then add 30% sodium hydroxide aqueous solution to pH to 10, oily matter precipitates out, extract with toluene 20ml×3, concentrate to obtain (1R,2S)-(-)-ephedrine and a little pseudoephedrine.

其盐酸盐制备如下:Its hydrochloride was prepared as follows:

以4N盐酸中和甲苯层至pH至4,分去甲苯,水层浓缩,得白色固体,以水重结晶,得12.2g(1R,2S)-(-)-麻黄碱盐酸盐,mp217.2-218.6℃,[α]D-34.1°(c=5.0,H2O),收率:75.3%。Neutralize the toluene layer with 4N hydrochloric acid until the pH reaches 4, remove the toluene, and concentrate the water layer to obtain a white solid, which is recrystallized with water to obtain 12.2 g of (1R, 2S)-(-)-ephedrine hydrochloride, mp217. 2-218.6°C, [α] D -34.1° (c=5.0, H 2 O), yield: 75.3%.

                       实施例3~5Example 3-5

采用与实施例1相同的方法,以乙醇为溶剂,分别以20.7g[(S)-(-)-α-甲胺基苯丙酮]2·(2R,3R)-(-)-二对甲基苯甲酰基酒石酸(实施例3)、13.9g[(S)-(-)-α-甲胺基苯丙酮]2·d-酒石酸(实施例4)和13.5g[(S)-(-)-α-甲胺基苯丙酮]2·苹果酸(实施例5)为原料,分别获得8.3g、8.4g和8.2g(1R,2S)-(-)-麻黄碱盐酸盐;mp 217.2-218.6℃,[α]D-34.1°(c=5.0,H2O)Using the same method as in Example 1, with ethanol as the solvent, 20.7g [(S)-(-)-α-methylaminopropiophenone] 2 ·(2R, 3R)-(-)-di-p-methyl Benzoyl tartaric acid (embodiment 3), 13.9g [(S)-(-)-α-methylaminopropiophenone] 2.d -tartaric acid (embodiment 4) and 13.5g [(S)-(- )-alpha-methylaminopropiophenone] 2. malic acid (embodiment 5) is raw material, respectively obtains 8.3g, 8.4g and 8.2g (1R, 2S)-(-)-ephedrine hydrochloride; mp 217.2 -218.6°C, [α] D -34.1° (c=5.0, H2O)

收率分别为70.1%,71.3%和74.8%。The yields were 70.1%, 71.3% and 74.8%, respectively.

                       实施例6Example 6

采用与实施例1相同的方法,以甲醇为溶剂,并加入0.1g AlCl3,获得8.3g(1R,2S)-(-)-麻黄碱盐酸盐;mp 217.2-218.6℃,[α]D-34.10(c=5.0,H2O)收率为70.1%。Adopt the method identical with embodiment 1, take methanol as solvent, and add 0.1g AlCl3, obtain 8.3g (1R, 2S)-(-)-ephedrine hydrochloride; mp 217.2-218.6 ℃, [α]D- 34.10 (c=5.0, H2O) Yield 70.1%.

Claims (6)

1.(1R,2S)-(-)-麻黄碱的制备方法,其特征在于包括如下步骤:1. (1R, 2S)-(-)-the preparation method of ephedrine is characterized in that comprising the steps: 将还原剂加入含有反应原料的溶剂中进行还原反应,然后采用常规的方法后处理即可得(1R,2S)-(-)-麻黄碱;The reducing agent is added to the solvent containing the reaction raw materials to carry out the reduction reaction, and then post-treatment by conventional methods to obtain (1R, 2S)-(-)-ephedrine; 所说的反应原料包括:[(S)-(-)-α-甲胺基苯丙酮]2·(2R,3R)-(-)-二苯甲酰基酒石酸、[(S)-(-)-α-甲胺基苯丙酮]2·(2R,3R)-(-)-二对甲基苯甲酰基酒石酸、[(S)-(-)-α-甲胺基苯丙酮]2·(2R,3R)-(-)-二间甲基苯甲酰基酒石酸、[(S)-(-)-α-甲胺基苯丙酮]2·(2R,3R)-(-)-二邻甲基苯甲酰基酒石酸、[(S)-(-)-α-甲胺基苯丙酮]2·(2R,3R)-(-)-二乙酰基酒石酸、[(S)-(-)-α-甲胺基苯丙酮]2·邻苯二甲酸、[(S)-(-)-α-甲胺基苯丙酮]2·d-酒石酸、(S)-(-)-α-甲胺基苯丙酮·苯甲酸、(S)-(-)-α-甲胺基苯丙酮·苹果酸及(S)-(-)-α-甲胺基苯丙酮·乳酸中的一种;Said reaction raw materials include: [(S)-(-)-α-methylaminopropiophenone] 2 ·(2R, 3R)-(-)-dibenzoyl tartaric acid, [(S)-(-) -α-methylaminopropiophenone] 2 ·(2R,3R)-(-)-di-p-methylbenzoyl tartaric acid, [(S)-(-)-α-methylaminopropiophenone] 2 ·( 2R, 3R)-(-)-di-m-toluoyl tartaric acid, [(S)-(-)-α-methylaminopropiophenone] 2 · (2R, 3R)-(-)-di-o-methyl benzoyl tartaric acid, [(S)-(-)-α-methylaminopropiophenone] 2 ·(2R,3R)-(-)-diacetyltartaric acid, [(S)-(-)-α -methylaminopropiophenone] 2 phthalic acid, [(S)-(-)-α-methylaminopropiophenone] 2 d-tartaric acid, (S)-(-)-α-methylamino One of propiophenone·benzoic acid, (S)-(-)-α-methylaminopropiophenone·malic acid and (S)-(-)-α-methylaminopropiophenone·lactic acid; 还原剂为金属硼氢化物或金属硼氢化物与路易斯酸组成的混合物。The reducing agent is metal borohydride or a mixture of metal borohydride and Lewis acid. 2.根据权利要求1所述的方法,其特征在于,所说的溶剂选自水、C1~C5的醇或水与C1~C5的醇组成的混合物。2. The method according to claim 1, characterized in that said solvent is selected from water, C1-C5 alcohol or a mixture of water and C1-C5 alcohol. 3.根据权利要求1所述的方法,其特征在于,反应温度为-20~35℃。3. The method according to claim 1, characterized in that the reaction temperature is -20 to 35°C. 4.根据权利要求1所述的方法,其特征在于,所说的金属硼氢化物选自KBH4、NaBH4、Zn(BH4)2、LiBH4或Ca(BH4)2中的一种。4. The method according to claim 1, wherein said metal borohydride is selected from one of KBH 4 , NaBH 4 , Zn(BH 4 ) 2 , LiBH 4 or Ca(BH 4 ) 2 . 5.根据权利要求1所述的方法,其特征在于,所说的路易斯酸选自AlCl3、CaCl2或ZnCl25. The method according to claim 1, characterized in that said Lewis acid is selected from AlCl 3 , CaCl 2 or ZnCl 2 . 6.根据权利要求1~5任一项所述的方法,其特征在于,反应原料与还原剂的摩尔比为:反应原料∶还原剂=1∶0.5~3。6. The method according to any one of claims 1-5, characterized in that the molar ratio of the reaction raw material to the reducing agent is: reaction raw material:reducing agent=1:0.5-3.
CNB2004100249538A 2004-06-07 2004-06-07 Prepn process of (1R, 2S)-(-)-ephedrine or its hydrochloride Expired - Lifetime CN1293038C (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CNB2004100249538A CN1293038C (en) 2004-06-07 2004-06-07 Prepn process of (1R, 2S)-(-)-ephedrine or its hydrochloride
PCT/CN2005/000743 WO2005121066A1 (en) 2004-06-07 2005-05-27 The preparation method of (1 r,2s)-(-)-ephedrine or its hydrochloride

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB2004100249538A CN1293038C (en) 2004-06-07 2004-06-07 Prepn process of (1R, 2S)-(-)-ephedrine or its hydrochloride

Publications (2)

Publication Number Publication Date
CN1706812A CN1706812A (en) 2005-12-14
CN1293038C true CN1293038C (en) 2007-01-03

Family

ID=35502989

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2004100249538A Expired - Lifetime CN1293038C (en) 2004-06-07 2004-06-07 Prepn process of (1R, 2S)-(-)-ephedrine or its hydrochloride

Country Status (2)

Country Link
CN (1) CN1293038C (en)
WO (1) WO2005121066A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101870660A (en) * 2010-05-10 2010-10-27 青海省青海湖药业有限公司 Preparation method of L-(-)-ephedrine chloride and d-(+)-pseudoephedrine hydrochloride
CN102399158B (en) * 2010-09-16 2014-04-02 哈尔滨工业大学 Chemical technology for preparing ephedrine
CN106008183B (en) * 2016-06-07 2019-05-07 浙江普洛康裕制药有限公司 Preparation method of ephedrine or pseudoephedrine and ephedrine or pseudoephedrine intermediate

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD94396A (en) *

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD94396A (en) *

Also Published As

Publication number Publication date
WO2005121066A1 (en) 2005-12-22
CN1706812A (en) 2005-12-14

Similar Documents

Publication Publication Date Title
CN1183082C (en) Preparation method of (2R) -2-propyl octanoic acid
CN1179939C (en) How to make epinephrine
CN1293038C (en) Prepn process of (1R, 2S)-(-)-ephedrine or its hydrochloride
US20120178929A1 (en) Method for preparing halofuginone derivative
US20100076086A1 (en) Process for the preparation of o-desmethyl venlafaxine
WO2014057495A1 (en) A process for industrial preparation of [(s)-n-tert butoxycarbonyl-3-hydroxy]adamantylglycine
CN1289465C (en) Process for preparing (R) salbutamol
CN1485315A (en) 3, the preparation method of 4'-diaminodiphenyl ether
US20100063160A1 (en) Polymorphs of o-desmethyl venlafaxine succinate
CN104326927B (en) A kind of preparation method of 1-[2-amino-1-(4-methoxyphenyl) ethyl] Hexalin sulfate
CN1990455A (en) Simple and novel process for preparing indenes derivatives
CN1927813A (en) Synthesis method of levorotatory albuterol hydrochloride
CN111196759B (en) Preparation method of cinacalcet hydrochloride and intermediate thereof
CN1715275A (en) Simple process for preparing trimetazidine and its medicinal salts
NZ503397A (en) 3-amino-3-arylpropan-1-ol derivatives, and their preparation and use as a medicament in the treatment of chronic pain and other illnesses
KR100829894B1 (en) Method for preparing dimacrotic acid and its magnesium salt
CN118834135A (en) A kind of preparation method of ambroxol hydrochloride
US8063251B2 (en) Process for the preparation of optically pure R (−) salbutamol and its pharmaceutically acceptable salts
CN1399626A (en) Methylvenlafaxine ether
CN116693409A (en) Preparation method of (2S) - [4- (3-fluorobenzyloxy) benzylamino ] methyl propionate
CN116354835A (en) Preparation method of venlafaxine hydrochloride EP impurity H
CN108148039A (en) A kind of preparation method of depression bulk pharmaceutical chemicals
KR100342919B1 (en) A preparation and purification for trans isomer of tramadol hydrochloride
CN113717068A (en) Phenyladrenaline impurity and preparation method and application thereof
CN101279926A (en) Preparation of venlafaxine hydrochloride crystal Form I

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee
CP01 Change in the name or title of a patent holder

Address after: 200040 Beijing West Road, Shanghai, No. 1320

Patentee after: SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY

Patentee after: ZHEJIANG APELOA KANGYU PHARMACEUTICAL Co.,Ltd.

Address before: 200040 Beijing West Road, Shanghai, No. 1320

Patentee before: Shanghai Institute of pharmaceutical industry

Patentee before: ZHEJIANG KANGYU PHARMACEUTICAL Co.,Ltd.

TR01 Transfer of patent right

Effective date of registration: 20200714

Address after: No.399, Jiangnan Road, Hengdian Town, Dongyang City, Zhejiang Province

Co-patentee after: SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY

Patentee after: APELOA PHARMACEUTICAL Co.,Ltd.

Co-patentee after: ZHEJIANG APELOA KANGYU PHARMACEUTICAL Co.,Ltd.

Address before: 200040 No. 1320 West Beijing Road, Shanghai

Co-patentee before: ZHEJIANG APELOA KANGYU PHARMACEUTICAL Co.,Ltd.

Patentee before: SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY

TR01 Transfer of patent right
DD01 Delivery of document by public notice

Addressee: Xu Wei

Document name: Notification of Passing Examination on Formalities

DD01 Delivery of document by public notice
CX01 Expiry of patent term

Granted publication date: 20070103

CX01 Expiry of patent term